Cargando…

Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer

(1) Background: recent evidence suggests that long low-dose capecitabine regimens have a synergistic effect with endocrine therapy as aromatase inhibitors (AIs), and might increase overall survival for hormone-receptor-positive, HER2-negative, metastatic breast cancer compared to both treatments. We...

Descripción completa

Detalles Bibliográficos
Autores principales: Alvarado-Miranda, Alberto, Lara-Medina, Fernando Ulises, Muñoz-Montaño, Wendy R., Zinser-Sierra, Juan W., Galeana, Paula Anel Cabrera, Garza, Cynthia Villarreal, Sanchez Benitez, Daniel, Limón Rodríguez, Jesús Alberto, Arce Salinas, Claudia Haydee, Guijosa, Alberto, Arrieta, Oscar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377785/
https://www.ncbi.nlm.nih.gov/pubmed/37504314
http://dx.doi.org/10.3390/curroncol30070454
_version_ 1785079603211010048
author Alvarado-Miranda, Alberto
Lara-Medina, Fernando Ulises
Muñoz-Montaño, Wendy R.
Zinser-Sierra, Juan W.
Galeana, Paula Anel Cabrera
Garza, Cynthia Villarreal
Sanchez Benitez, Daniel
Limón Rodríguez, Jesús Alberto
Arce Salinas, Claudia Haydee
Guijosa, Alberto
Arrieta, Oscar
author_facet Alvarado-Miranda, Alberto
Lara-Medina, Fernando Ulises
Muñoz-Montaño, Wendy R.
Zinser-Sierra, Juan W.
Galeana, Paula Anel Cabrera
Garza, Cynthia Villarreal
Sanchez Benitez, Daniel
Limón Rodríguez, Jesús Alberto
Arce Salinas, Claudia Haydee
Guijosa, Alberto
Arrieta, Oscar
author_sort Alvarado-Miranda, Alberto
collection PubMed
description (1) Background: recent evidence suggests that long low-dose capecitabine regimens have a synergistic effect with endocrine therapy as aromatase inhibitors (AIs), and might increase overall survival for hormone-receptor-positive, HER2-negative, metastatic breast cancer compared to both treatments. We performed a retrospective study to confirm the efficacy and expand the safety data for capecitabine plus AI (a combination henceforth named XELIA) for this indication. (2) We conducted a single-center retrospective cohort study of 163 hormone receptor-positive metastatic breast cancer patients who received either the XELIA regimen, capecitabine, or an aromatase inhibitor (AI) as single agents in first-line treatment. The primary endpoint was progression-free survival, and the secondary endpoints were overall survival, best objective response, and toxicity incidence. (3) Results: the median progression-free survival for patients receiving XELIA, AI, and capecitabine was 29.37 months (20.91 to 37.84; 95% CI), 20.04 months (7.29 to 32.80; 95% CI) and 10.48 (8.69 to 12.28; 95% CI), respectively. The overall response rate was higher in the XELIA group (29.5%) than in the AI (14.3%) and capecitabine (9.1%) groups. However, the differences in overall survival were not statistically significant. Apart from hand–foot syndrome, there were no statistically significant differences in adverse events between the groups. (4) Conclusions: this retrospective study suggests that progression-free survival and overall response rates improved with the XELIA regimen compared to use of aromatase inhibitors and capecitabine alone. Combined use demonstrated an adequate safety profile and might represent an advantageous treatment in places where CDK 4/6 is not available. Larger studies and randomized clinical trials are required to confirm the effects shown in our study.
format Online
Article
Text
id pubmed-10377785
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103777852023-07-29 Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer Alvarado-Miranda, Alberto Lara-Medina, Fernando Ulises Muñoz-Montaño, Wendy R. Zinser-Sierra, Juan W. Galeana, Paula Anel Cabrera Garza, Cynthia Villarreal Sanchez Benitez, Daniel Limón Rodríguez, Jesús Alberto Arce Salinas, Claudia Haydee Guijosa, Alberto Arrieta, Oscar Curr Oncol Article (1) Background: recent evidence suggests that long low-dose capecitabine regimens have a synergistic effect with endocrine therapy as aromatase inhibitors (AIs), and might increase overall survival for hormone-receptor-positive, HER2-negative, metastatic breast cancer compared to both treatments. We performed a retrospective study to confirm the efficacy and expand the safety data for capecitabine plus AI (a combination henceforth named XELIA) for this indication. (2) We conducted a single-center retrospective cohort study of 163 hormone receptor-positive metastatic breast cancer patients who received either the XELIA regimen, capecitabine, or an aromatase inhibitor (AI) as single agents in first-line treatment. The primary endpoint was progression-free survival, and the secondary endpoints were overall survival, best objective response, and toxicity incidence. (3) Results: the median progression-free survival for patients receiving XELIA, AI, and capecitabine was 29.37 months (20.91 to 37.84; 95% CI), 20.04 months (7.29 to 32.80; 95% CI) and 10.48 (8.69 to 12.28; 95% CI), respectively. The overall response rate was higher in the XELIA group (29.5%) than in the AI (14.3%) and capecitabine (9.1%) groups. However, the differences in overall survival were not statistically significant. Apart from hand–foot syndrome, there were no statistically significant differences in adverse events between the groups. (4) Conclusions: this retrospective study suggests that progression-free survival and overall response rates improved with the XELIA regimen compared to use of aromatase inhibitors and capecitabine alone. Combined use demonstrated an adequate safety profile and might represent an advantageous treatment in places where CDK 4/6 is not available. Larger studies and randomized clinical trials are required to confirm the effects shown in our study. MDPI 2023-06-24 /pmc/articles/PMC10377785/ /pubmed/37504314 http://dx.doi.org/10.3390/curroncol30070454 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Alvarado-Miranda, Alberto
Lara-Medina, Fernando Ulises
Muñoz-Montaño, Wendy R.
Zinser-Sierra, Juan W.
Galeana, Paula Anel Cabrera
Garza, Cynthia Villarreal
Sanchez Benitez, Daniel
Limón Rodríguez, Jesús Alberto
Arce Salinas, Claudia Haydee
Guijosa, Alberto
Arrieta, Oscar
Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
title Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
title_full Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
title_fullStr Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
title_full_unstemmed Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
title_short Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
title_sort capecitabine plus aromatase inhibitor as first line therapy for hormone receptor positive, her2 negative metastatic breast cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377785/
https://www.ncbi.nlm.nih.gov/pubmed/37504314
http://dx.doi.org/10.3390/curroncol30070454
work_keys_str_mv AT alvaradomirandaalberto capecitabineplusaromataseinhibitorasfirstlinetherapyforhormonereceptorpositiveher2negativemetastaticbreastcancer
AT laramedinafernandoulises capecitabineplusaromataseinhibitorasfirstlinetherapyforhormonereceptorpositiveher2negativemetastaticbreastcancer
AT munozmontanowendyr capecitabineplusaromataseinhibitorasfirstlinetherapyforhormonereceptorpositiveher2negativemetastaticbreastcancer
AT zinsersierrajuanw capecitabineplusaromataseinhibitorasfirstlinetherapyforhormonereceptorpositiveher2negativemetastaticbreastcancer
AT galeanapaulaanelcabrera capecitabineplusaromataseinhibitorasfirstlinetherapyforhormonereceptorpositiveher2negativemetastaticbreastcancer
AT garzacynthiavillarreal capecitabineplusaromataseinhibitorasfirstlinetherapyforhormonereceptorpositiveher2negativemetastaticbreastcancer
AT sanchezbenitezdaniel capecitabineplusaromataseinhibitorasfirstlinetherapyforhormonereceptorpositiveher2negativemetastaticbreastcancer
AT limonrodriguezjesusalberto capecitabineplusaromataseinhibitorasfirstlinetherapyforhormonereceptorpositiveher2negativemetastaticbreastcancer
AT arcesalinasclaudiahaydee capecitabineplusaromataseinhibitorasfirstlinetherapyforhormonereceptorpositiveher2negativemetastaticbreastcancer
AT guijosaalberto capecitabineplusaromataseinhibitorasfirstlinetherapyforhormonereceptorpositiveher2negativemetastaticbreastcancer
AT arrietaoscar capecitabineplusaromataseinhibitorasfirstlinetherapyforhormonereceptorpositiveher2negativemetastaticbreastcancer